BACKGROUND:Hepatitis C virus (HCV) is a frequent copathogen with HIV. Both viruses appear to replicate in the brain and both are implicated in neurocognitive and peripheral neuropathy syndromes. Interaction of the viruses is likely to be complicated and better understanding of the contributions of each virus will be necessary to make evidence-based therapeutic decisions. METHODS: This study was designed to determine if active HCV infection, identified by quantitative HCV RNA determination, is associated with increased neurocognitive deficits or excess development of distal sensory peripheral neuropathy in HIV coinfected patients with stable HIV viral suppression. The AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) study was the source of subjects with known HIV treatment status, neurocognitive and neuropathy evaluations, and HCV status. Subjects were selected based on HCV antibody status (249 positive; 310 negative). RESULTS:HCV RNA viral loads were detectable in 172 participants with controlled HIV infection and available neurologic evaluations in the ALLRT. These participants were compared with 345 participants with undetectable HCV viral load and the same inclusion criteria from the same cohort. Neurocognitive performance measured by Trail-Making A or B and digit symbol testing was not dissimilar between the 2 groups. In addition, there was no significant association between active HCV replication and distal sensory neuropathy. CONCLUSION: Clinically significant neurocognitive dysfunction and peripheral neuropathy were not exacerbated by active hepatitis C virus infection in the setting of optimally treated HIV infection.
RCT Entities:
BACKGROUND:Hepatitis C virus (HCV) is a frequent copathogen with HIV. Both viruses appear to replicate in the brain and both are implicated in neurocognitive and peripheral neuropathy syndromes. Interaction of the viruses is likely to be complicated and better understanding of the contributions of each virus will be necessary to make evidence-based therapeutic decisions. METHODS: This study was designed to determine if active HCV infection, identified by quantitative HCV RNA determination, is associated with increased neurocognitive deficits or excess development of distal sensory peripheral neuropathy in HIV coinfectedpatients with stable HIV viral suppression. The AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) study was the source of subjects with known HIV treatment status, neurocognitive and neuropathy evaluations, and HCV status. Subjects were selected based on HCV antibody status (249 positive; 310 negative). RESULTS:HCV RNA viral loads were detectable in 172 participants with controlled HIV infection and available neurologic evaluations in the ALLRT. These participants were compared with 345 participants with undetectable HCV viral load and the same inclusion criteria from the same cohort. Neurocognitive performance measured by Trail-Making A or B and digit symbol testing was not dissimilar between the 2 groups. In addition, there was no significant association between active HCV replication and distal sensory neuropathy. CONCLUSION: Clinically significant neurocognitive dysfunction and peripheral neuropathy were not exacerbated by active hepatitis C virus infection in the setting of optimally treated HIV infection.
Authors: Daniel M Forton; Howard C Thomas; Christine A Murphy; Joanna M Allsop; Graham R Foster; Janice Main; Keith A Wesnes; Simon D Taylor-Robinson Journal: Hepatology Date: 2002-02 Impact factor: 17.425
Authors: Thomas D Parsons; Karen A Tucker; Colin D Hall; Wendy T Robertson; Joseph J Eron; Michael W Fried; Kevin R Robertson Journal: AIDS Date: 2006-08-01 Impact factor: 4.177
Authors: Ludwig Kramer; Edith Bauer; Georg Funk; Harald Hofer; Wolfgang Jessner; Petra Steindl-Munda; Friedrich Wrba; Christian Madl; Alfred Gangl; Peter Ferenci Journal: J Hepatol Date: 2002-09 Impact factor: 25.083
Authors: Daniel M Forton; Peter Karayiannis; Nadiya Mahmud; Simon D Taylor-Robinson; Howard C Thomas Journal: J Virol Date: 2004-05 Impact factor: 5.103
Authors: C L Cherry; J S Affandi; B J Brew; J Creighton; S Djauzi; D J Hooker; D Imran; A Kamarulzaman; P Kamerman; J C McArthur; R D Moore; P Price; K Smyth; I L Tan; S Vanar; A Wadley; S L Wesselingh; E Yunihastuti Journal: Neurology Date: 2010-05-11 Impact factor: 9.910
Authors: Howard Crystal; Inna Kleyman; Kathryn Anastos; Jason Lazar; Mardge Cohen; Chenglong Liu; Leigh Pearce; Elizabeth Golub; Victor Valcour; Ann Ho; Howard Strickler; Marion Peters; Andrea Kovacs; Susan Holman; Mary Jeanne Kreek; Jennifer Manly Journal: J Acquir Immune Defic Syndr Date: 2012-02-01 Impact factor: 3.731
Authors: Taylor Kuhn; Philip Sayegh; Jacob D Jones; Jason Smith; Manoj K Sarma; A Ragin; Elyse J Singer; M Albert Thomas; April D Thames; Steven A Castellon; Charles H Hinkin Journal: J Neurovirol Date: 2017-05-30 Impact factor: 2.643
Authors: Huichao Chen; David B Clifford; Lijuan Deng; Kunling Wu; Anthony J Lee; Ronald J Bosch; Sharon A Riddler; Ronald J Ellis; Scott R Evans Journal: J Neurovirol Date: 2013-12-03 Impact factor: 2.643